TP53 and breast carcinoma: In human breast cancer MCF-7 cells, JNK plays a crucial role in the ROS/MAPK molecular pathway, leading to synthetic lethality upon p53 activation and TrxR inhibition [14]; ROS/MAPK activation by TBBPA-induced NOX plays an important role in MMP-9 expression, and treatment with PD (ERK inhibitor), SP (JNK inhibitor), or SB (p38 MAPK inhibitor) blocked the ROS/MAPK molecular pathways [15].